<DOC>
	<DOC>NCT00279773</DOC>
	<brief_summary>The primary objective is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of TKI258 when administered to subjects with acute myeloid leukemia (AML).</brief_summary>
	<brief_title>Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<criteria>Confirmed diagnosis of Acute Myeloid Leukemia Eighteen years of age or older Life expectancy of at least 2 months Intracranial disease or epidural disease Clinically significant cardiac disease Diabetes mellitus uncontrolled with medication Pregnant or breast feeding women Dementia or altered mental status Known preexisting clinically significant or uncontrolled disorder of the hypothalamicpituitary axis, adrenal or thyroid glands Previous pericarditis Malabsorption syndrome or uncontrolled gastrointestinal symptoms such as nausea,diarrhea,vomiting</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Acute</keyword>
	<keyword>Myeloid</keyword>
	<keyword>Leukemia</keyword>
</DOC>